The firm has launched both a public offering of common stock as well as a private placement of warrants, expecting to bring in around $20 million from the transactions.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
Exagen, which develops and markets autoimmune tests, went public on the Nasdaq today and expects gross proceeds of $50.4 million from its IPO.
The industry organization issued a letter urging the agency to reconsider recent decisions to demand several laboratories stop offering pharmacogenetic testing.
The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
Progenity gains 137 granted patents and 15 pending applications in the US, Europe, China, and Japan in the deal.
The firm said that investigators will evaluate the clinical benefit of its assay using blood samples from a clinical trial for women with metastatic hormone receptor-positive breast cancer.
The German diagnostics firm recently signed an agreement to be acquired by US-based OpGen in a transaction that is slated to close in early 2020.
The firm said that it ended a distributor agreement that it had inked in 2013 with Fosun Long March Medical Science and Shanghai Xin Chang Medical Device.
The credit facility, available through Sept. 17, 2024, replaces a prior credit facility dated Aug. 11, 2016 for $1 billion.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
CellaVision is paying about $27.7 million for the deal, and is being funded through a combination of cash, cash equivalents, and a loan.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
A jury last week determined Quest did not steal trade secrets from Cedars-Sinai or breach its contract with the hospital in developing a serological IBS test.
PWNHealth will provide physician oversight and genetic counseling for Picture Genetics, a new line of three genetic tests from Fulgent aimed at consumers.
The solutions are solutions for both clinical chemistry and immunoassay platforms and are meant to help labs run tests faster on less equipment and automate manual tasks.
The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.
A JAMA study found that low-value diagnostic tests are common in inpatient settings, and machine learning systems can be used to identify those tests and reduce their overutilization.
The mass spec test is designed to measure blood-based proteins to predict type 2 diabetes patients' risk of developing diabetic kidney disease.
The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.
The tests are designed to monitor a patient's immune system for cancer responses rather than looking for tumor cells or specific biomarkers.